Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Sema4 was a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Founded in 2017 as a spin-off from the Mount Sinai Health System, Sema4 leveraged artificial intelligence and machine learning to analyze large-scale clinical and genomic data, aiming to deliver precision medicine solutions for complex diseases, initially focusing on women's health, oncology, and rare diseases. The company provided advanced genomic testing and services to physicians and patients. In January 2023, Sema4 was acquired by GeneDx, and the combined company now operates under the GeneDx name.
Served as the main corporate office, housing executive leadership, administrative functions, R&D, and data science teams. It was central to strategic planning and operations.
The Stamford facilities included modern office spaces and potentially integrated laboratory capabilities, designed to foster collaboration and innovation.
Sema4's work culture was characterized by a strong emphasis on scientific innovation, data-driven decision-making, and a mission to improve patient outcomes. It fostered a collaborative environment for researchers, clinicians, and technologists.
The Stamford headquarters was pivotal as the command center for Sema4's efforts in building its health intelligence platform and expanding its genomic testing services across the United States.
Sema4's operations and market focus were primarily within the United States. It offered its health intelligence platform, genomic testing, and data analysis services to healthcare systems, physicians, and patients across the U.S. While it may have engaged in international research collaborations, its core infrastructure, laboratories, and commercial activities were U.S.-based.
333 Ludlow Street
Stamford
Connecticut
USA
Address: 620 West Main Street & 1 Commercial Street, Branford, CT 06405
Served as a primary hub for Sema4's laboratory services, processing patient samples and generating genomic data for analysis.
Address: 142 East 30th Street, New York, NY (and other Mount Sinai affiliated locations)
Facilitated close ties with the academic and clinical research community in NYC, particularly with Mount Sinai, and supported specialized teams.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Sema4' leadership includes:
Sema4 has been backed by several prominent investors over the years, including:
Sema4 experienced key leadership changes in the period leading up to its acquisition by GeneDx, including a new CEO and CFO transitions.
Discover the tools Sema4 uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Sema4 commonly used a standard corporate email format. Based on available information and common practices, the most likely format involved the employee's first and last name.
firstname.lastname@sema4.com
Format
jane.doe@sema4.com
Example
85%
Success rate
GenomeWeb • May 16, 2022
Sema4 announced its definitive agreement to acquire GeneDx, a leader in genomic testing for rare disorders, from Opko Health. The deal aimed to create a large and comprehensive health information company....more
Sema4 Press Release • February 1, 2022
Sema4 announced the appointment of Katherine Stueland as its new Chief Executive Officer. Founder Eric Schadt, Ph.D., transitioned to the role of Chief R&D Officer....more
Sema4 Press Release • July 22, 2021
Sema4 announced the completion of its business combination with CM Life Sciences, a special purpose acquisition company (SPAC), and began trading on the Nasdaq stock exchange under the ticker 'SMFR'....more
Fierce Biotech • June 1, 2021
Sema4 raised $121 million in a Series C funding round led by existing investor Section 32, with participation from new and existing investors, to further develop its health intelligence platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Sema4, are just a search away.